BioPharma
Why Only 1 in 4 People with ALS Can Realistically Access Clinical trials
Dennis Akkaya
21 Aug 2026
12 mins read
MFN Drug Pricing and Global Access Challenges: Why Chargeable Expanded Access is More Critical Than Ever Before
Stephanie Ferket
15 Apr 2026
15 mins read
Our next chapter: €25M growth investment to scale patient access worldwide
Michel van Harten
11 Nov 2025
7 mins read
Accelerating ALS Clinical Trial Recruitment in the U.S.
Dennis Akkaya
10 Oct 2025
12 mins read
Why A Purpose-Built Platform for Expanded Access Management Matters
Dennis Akkaya
28 May 2025
7 mins read
A BioPharma Guide to Expanded Access Program Management and Real-World Data
myTomorrows Team
17 Feb 2025
5 mins read
Transforming Clinical Research: myTomorrows’ GenAI Solution for Universal Trial Access
myTomorrows Team
6 Feb 2025
6 mins read
Building Effective Diversity, Equity, and Inclusion Strategies in Clinical Trial Recruitment
myTomorrows Team
6 Aug 2024
9 mins read
Unlocking the potential of Real-World Evidence derived from Expanded Access Programs
myTomorrows Team
24 Apr 2024
8 mins read
Boosting Clinical Trial Enrollment by Reducing Participation Barriers
Dennis Akkaya
31 Jan 2023
6 mins read
The Race to Develop Rare Disease Treatments
myTomorrows Team
22 Dec 2022
9 mins read
Why It Is Important to Develop a Good Expanded Access Policy
Dennis Akkaya
8 Aug 2021
6 mins read
Expanded Access Program (Compassionate Use) Frameworks in Europe
Dennis Akkaya
27 May 2021
11 mins read
Key Considerations for Operationalizing an Expanded Access Program
Dennis Akkaya
16 Feb 2021
11 mins read
Post-Trial Access to Treatment: How Expanded Access Can Offer A Strategic Solution
Dennis Akkaya
2 Sep 2020
19 mins read
A Brief History of Expanded Access (Pt. 2) 2014 – 2020
Dennis Akkaya
10 Jun 2020
8 mins read
A Brief History of Expanded Access (Pt. 1) 1960 – 2009
Dennis Akkaya
25 May 2020
7 mins read
Understanding Expanded Access, Compassionate Use and Similar Terms
Dennis Akkaya
18 May 2020
7 mins read
Accessing Investigational New Drugs
Dennis Akkaya
30 Apr 2020
7 mins read
